Escitalopram
From Pharmacopedia
More actions
Escitalopram
Lexapro
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Major depressive disorder (FDA, ages 12+)0, Generalized anxiety disorder (FDA, adult)0, Panic disorder (off-label)0, Obsessive-compulsive disorder (off-label)0, Posttraumatic stress disorder (off-label)0, Premenstrual dysphoric disorder (off-label)0, Menopausal vasomotor symptoms (off-label)0
Pharmacy
Starting dose
10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed
Preparations
Tablets 5, 10, 20 mg; oral solution 1 mg/mL
US FDA Max
20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment
Pharmacology
Routes
Oral
Onset
Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks
Duration
24 hours (once-daily dosing)
Half-life
27-32 hours[2]
Bioavailability
~80% (oral)[2]
Pregnancy
Observational signal for persistent pulmonary hypertension of the newborn (small absolute risk) and neonatal adaptation syndrome with third-trimester exposure; weigh against the risks of untreated maternal depression.[citation needed]
Legal status
Purported mechanism
Highly selective serotonin reuptake inhibitor. Escitalopram is the (S)-enantiomer of citalopram, which carries essentially all of the serotonin transporter (SERT) binding activity; the (R)-enantiomer contributes little SERT activity and may carry the QT-prolonging liability that prompted the FDA's 2011 citalopram dose ceiling, giving escitalopram a more favorable QT profile.0 CYP2C19 + CYP3A4 metabolism, with CPIC PGx guidance: poor CYP2C19 metabolizers have ~3-fold higher exposure and benefit from a lower starting dose; ultrarapid metabolizers may have inadequate response[1].
References
- ↑ CPIC Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, 2023. https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/
- ↑ 2.0 2.1 2.2 FDA Prescribing Information, Lexapro (escitalopram oxalate), AbbVie/Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf